INmune Bio Option Alert: Jul 18 $10 Calls Sweep (8) near the Ask: 1024 vs 3570 OI; Earnings 7/31 After Close [est] 

INmune Bio Option Alert: Jul 18 $10 Calls Sweep (8) near the Ask: 1024 @ $5.5 vs 3570 OI; Earnings 7/31 After Close [est] Ref=$10.92

INmune Bio (NASDAQ:INMB) Stock

INmune Bio

INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.

INmune Bio Inc

WIIM

INMB

INMB stock has given up its prior gain. INmune Bio shares were trading higher after the company revealed top-line results from its MINDFuL Phase 2 trial.

<a href="https://x.com/adamfeuerstein/status/1938636778950602947">https://x.com/adamfeuerstein/status/1938636778950602947</a>

News

General

STAT News Biotech Reporter Adam Feuerstein Posts On X "$INMB raised money today with full knowledge of the Alzheimer's study data, per a source familiar with the transaction."

INmune Bio Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) (the "Company"), a clinical-stage inflammation and immunology company, today announced that it has entered into securities purchase agreements with two healthcare focused institutional investors for the purchase and sale of 3,000,000 shares of its common stock in a registered direct offering (the "Offering") at a purchase price of $6.30 per share, priced at-the-market under Nasdaq rules.
The closing of the Offering is expected to occur on or about June 30, 2025, subject to the satisfaction of customary closing conditions. The gross proceeds from the Offering are expected to be approximately $19 million, before deducting placement agent fees and other estimated offering expenses. The Company intends to use the net proceeds from the Offering for working capital purposes and general corporate procedures.

Offerings

INmune Bio Prices 3M Share Registered Direct Offering At $6.30/Shr

INmune Bio Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) stock is trading higher on Friday, with a session volume of 10.26 million compared to the average volume of 519.5K, <a href="https://www.benzinga.com/pro/feature/newsfeed" target="_blank" rel="noreferrer noopener">per data from Benzinga Pro</a>.
On Thursday,  INmune Bio said it will host a conference call on Monday, June 30, to present topline data from the Phase 2 MINDFuL trial in early <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">Alzheimer&#8217;s disease</a>.
The MINDFuL study investigates XPro in patients with mild cognitive impairment or Alzheimer's disease with brain inflammation.
The MINDFuL study <a href="https://inmunebio.com/index.php/clinical-trials/mindful-section" target="_blank" rel="noreferrer noopener">will</a> compare XPro to placebo (an injection that looks like the investigational drug but does not contain active medicine) to determine whether XPro affects memory, functioning and behavior, and whether it is safe and tolerable.
In November 2024, INmune Bio completed randomization of patients for <a href="https://www.benzinga.com/pressreleases/24/11/g41939489/inmune-bio-inc-announces-final-enrollment-of-208-patients-in-phase-2-trial-in-early-alzheimers-dis" target="_blank" rel="noreferrer noopener">its Phase 2 trial</a>. &#8220;The trial ended up overenrolled with a total of 208 patients, 56% of whom were categorized as mild AD and 44% as MCI,&#8221; said RJ Tesi, CEO of INmune Bio
In September 2024, the company announced that the results of an additional analysis of blinded data from its AD02 Phase II Alzheimer&#8217;s Disease trial demonstrated&nbsp;exceptional performance of the novel cognitive measure EMACC and a highly significant correlation between EMACC and the Clinical Dementia Rating-Sum of Boxes (CDR-SB), the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g40897550/inmune-bio-announces-results-of-additional-blinded-interim-analysis-of-phase-2-alzheimers-disease-" rel="noreferrer noopener">accepted endpoint for AD trials.</a>
Key Findings: An independent review confirmed a highly significant correlation (p&lt;0.001) between baseline scores on EMACC and CDR-SB, the secondary endpoint in the AD02 trial.
The correlation of EMACC, when measured during the screening process and again at the first study visit before treatment, was found to be 0.93.
The difference in EMACC performance between patients with CDR global ratings of 0.5 (prodromal AD) and those rated 1.0 (mild dementia) was very large, with an effect size (Cohen&#8217;s d) of 0.87 (p&lt;.0001)
XPro is a next-generation inhibitor of tumor necrosis factor (TNF) that is currently in clinical trial and acts differently than currently available TNF inhibitors in that it neutralizes soluble TNF (sTNF), without affecting trans-membrane TNF (tmTNF) or TNF receptors.
XPro could have potential substantial beneficial effects in patients with neurologic disease by <a href="https://www.benzinga.com/pressreleases/25/06/g46127038/inmune-bio-inc-to-announce-top-line-results-from-mindful-phase-2-trial-in-early-alzheimers-on-mond" target="_blank" rel="noreferrer noopener">decreasing neuroinflammation</a>.
INMB Price Action: INMB stock is up 74.68% at $10.97 at publication on Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/m-a/25/06/46138385/deal-dispatch-darden-bahama-breeze-nba-ma-heats-up" target="_blank" rel="noreferrer noopener">Deal Dispatch: Darden Cools On Bahama Breeze, NBA M&amp;A Heats Up</a></li>
</ul>
Photo: khunkornStudio via Shutterstock

Biotech

Health Care

Movers

Trading Ideas

INmune Bio Stock Soars Friday On Alzheimer's Treatment Hopes

<h3>Gainers</h3>
<ul>
<li>Bone Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>) shares increased by 86.0% to $7.74 during Friday's pre-market session. The company's market cap stands at $2.2 million. </li>
<li>INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) stock rose 58.75% to $9.97. The market value of their outstanding shares is at $146.8 million. </li>
<li>NanoVibronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) shares moved upwards by 38.07% to $1.2. The company's market cap stands at $2.2 million. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) shares increased by 36.0% to $7.1. The market value of their outstanding shares is at $2.9 million. </li>
<li>Actuate Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACTU#NASDAQ">ACTU</a>) stock moved upwards by 28.69% to $7.49. The company's market cap stands at $114.1 million. </li>
<li>Baird Medical Investment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDMD#NASDAQ">BDMD</a>) shares rose 22.17% to $5.4. The company's market cap stands at $163.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) shares declined by 25.3% to $1.45 during Friday's pre-market session. The company's market cap stands at $3.9 million. The company's, Q4 earnings came out yesterday. </li>
<li>Y-mAbs Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) stock declined by 22.3% to $3.73. The company's market cap stands at $217.4 million. </li>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) stock decreased by 22.29% to $0.37. The market value of their outstanding shares is at $7.4 million. </li>
<li>Achieve Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHV#NASDAQ">ACHV</a>) stock decreased by 15.94% to $2.95. The company's market cap stands at $121.7 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) stock declined by 15.25% to $0.31. The company's market cap stands at $18.6 million. </li>
<li>Establishment Labs Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESTA#NASDAQ">ESTA</a>) stock fell 12.66% to $35.67. The market value of their outstanding shares is at $1.1 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACHV

ACTU

ADIL

AEMD

BBLG

BDMD

ESTA

GCTK

NAOV

PSTV

YMAB

12 Health Care Stocks Moving In Friday's Pre-Market Session

INmune Bio shares are trading higher after the company revealed top-line results from its MINDFuL Phase 2 trial.

NKE: 11% &#x7C; <a href="https://www.benzinga.com/node/46128469">Nike Q4 Earnings: Revenue Beat, EPS Beat, Headwinds Expected To Moderate Moving Forward, Company Playing 'Sport Offense'</a>
&nbsp;
BBLG: 188% &#x7C; <a href="https://www.benzinga.com/node/46136060">Bone Biologics Files USPTO Patent For rhNELL-1 Protein In Bone Regeneration Therapy</a>
&nbsp;
INMB: 130% &#x7C; <a href="https://www.benzinga.com/node/46127302">INmune Bio shares are trading higher after the company revealed top-line results from its MINDFuL Phase 2 trial.</a>

Market-Moving News for June 27th

<h3>Gainers</h3>
<ul>
<li>NanoVibronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) shares increased by 45.2% to $1.25 during Thursday's after-market session. The market value of their outstanding shares is at $2.2 million. </li>
<li>INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) shares increased by 41.08% to $8.86. The company's market cap stands at $172.3 million. </li>
<li>Actuate Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACTU#NASDAQ">ACTU</a>) shares increased by 18.04% to $6.87. The market value of their outstanding shares is at $126.3 million. </li>
<li>WORK Medical Tech Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WOK#NASDAQ">WOK</a>) shares increased by 13.32% to $0.84. The market value of their outstanding shares is at $17.8 million. </li>
<li>Vor Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VOR#NASDAQ">VOR</a>) stock rose 11.12% to $0.99. The company's market cap stands at $69.2 million. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) shares moved upwards by 7.83% to $5.63. The company's market cap stands at $4.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) stock decreased by 20.1% to $1.55 during Thursday's after-market session. The market value of their outstanding shares is at $3.1 million. As per the news, the Q4 earnings report came out today. </li>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) shares declined by 17.33% to $0.39. The company's market cap stands at $3.8 million. </li>
<li>Achieve Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHV#NASDAQ">ACHV</a>) shares decreased by 12.83% to $3.06. The market value of their outstanding shares is at $131.8 million. </li>
<li>Cormedix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) stock declined by 10.97% to $13.32. The market value of their outstanding shares is at $1.0 billion. </li>
<li>Lixte Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIXT#NASDAQ">LIXT</a>) stock fell 9.17% to $0.71. The company's market cap stands at $2.1 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) shares fell 8.6% to $0.34. The market value of their outstanding shares is at $16.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CRMD

LIXT

12 Health Care Stocks Moving In Thursday's After-Market Session

INmune Bio To Reveal Top Line Results from MINDFuL Phase 2 Trial In Early Alzheimer's On June 30th

XPro&#x2122; Treatment Post-TBI Prevents Short- and Long-Term Alzheimer's-like Pathology in transgenic mice

Events

INmune Bio Presented Poster Demonstrating Traumatic Brain Injury Increases Amyloid Deposition In High-risk Animals And Effects OF Administration Of XPro

INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.47) by 8.51 percent. This is a 29.51 percent increase over losses of $(0.61) per share from the same period last year. The company reported $50.00 thousand in sales this quarter. This is a 257.14 percent increase over sales of $14.00 thousand the same period last year.

Earnings

Earnings Beats

INmune Bio Q1 EPS $(0.43) Beats $(0.47) Estimate, Sales $50.00K Up From $14.00K YoY

AAOI

ABCL

ABEV

ACIC

ACIW

ACMR

ACTG

AFRM

AKAM

AKBA

ALGM

ALIT

ALRM

ALXO

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

AMPX

AMTX

APPN

APYX

AQMS

ARGX

ARHS

ARKO

ARLO

ASPN

ASTH

Adtalem Global Education Inc. Common Stock

ATGE

ATHM

ATUS

AUTL

AVAH

AVPT

AXGN

BAER

BBDC

BIGC

BILL

BIRD

BlackSky Technology Inc. Class A Common Stock

BKSY

BLFS

BLND

CARG

CARS

CBLL

CBUS

CCEC

CCOI

CCRD

CDTX

CION

CLAR

CLFD

CLNE

CLSK

CMPS

CMRE

CODX

COIN

COLD

COLL

COMP

CRNX

CRON

CROX

CRVS

CTEV

CTKB

CTLP

CVRX

DAVE

DCGO

DCTH

DIOD

DKNG

Earnings Scheduled For May 8, 2025

Shares of Calix, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CALX#NYSE">CALX</a>) rose sharply in today's pre-market trading as the company reported better-than-expected first-quarter financial results and issued strong <a href="https://in.benzinga.com/news/buybacks/25/04/44911715/calix-stock-jumps-on-strong-q1-earnings-100-million-buyback-increase">second-quarter guidance</a>.
After market close on Monday, cloud and managed services company Calix announced that its board increased its buyback authorization by an additional $100 million, bringing the total repurchase authorization up to $162.9 million.
Calix reported first-quarter revenue of $220.24 million, beating analyst estimates of $206.98 million. The company reported first-quarter adjusted earnings of 19 cents per share, beating estimates of 13 cents per share, according to Benzinga Pro.
Calix shares jumped 13.1% to $37.61 in pre-market trading
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Gelteq Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GELS#NASDAQ">GELS</a>) rose 329% to $3.97 in pre-market trading.</li>
<li>Standard Lithium Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLI#NYSE">SLI</a>) surged 44.2% to $2.02 in pre-market trading. Smackover Lithium&#8217;s South West Arkansas Project has received a special designation as a priority transparency critical mineral project from the Trump Administration.</li>
<li>SUNation Energy Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUNE#NASDAQ">SUNE</a>) gained 36.2% to $3.80 in pre-market after dipping 30% on Monday.</li>
<li>Mullen Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>) surged 25.3% to $1.09 in pre-market trading after dipping over 22% on Monday.</li>
<li>MicroCloud Hologram Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLO#NASDAQ">HOLO</a>) gained 25% to $15.25 in pre-market trading after falling around 20% on Monday.</li>
<li>IT Tech Packaging, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITP#NYSE">ITP</a>) jumped 22.4% to $0.2880 in pre-market trading after dipping 11% on Monday.</li>
<li>Meiwu Technology Company Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WNW#NASDAQ">WNW</a>) rose 21.8% to $1.51 in pre-market trading r after the company announced it regained Nasdaq compliance.</li>
<li>Solaris Resources Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLSR#NYSE">SLSR</a>) rose 17.4% to $3.98 in pre-market trading.</li>
<li>Adaptive Biotechnologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) gained 17% to $7.99 in pre-market trading. Adaptive Biotechnologies will report financial results for the first quarter after market close on Thursday, May 1.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>MKDWELL Tech Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKDW#NASDAQ">MKDW</a>) fell 43.5% to $0.22 in pre-market trading after jumping over 70% on Monday.</li>
<li>TNL Mediagene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNMG#NASDAQ">TNMG</a>) fell 36.7% to $0.1857 in pre-market trading after declining 5% on Monday.</li>
<li>SHF Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHFS#NASDAQ">SHFS</a>) shares fell 22.2% to $3.26 in pre-market trading after jumping around 96% on Monday.</li>
<li>Outset Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OM#NASDAQ">OM</a>) shares tumbled 16.8% to $8.30 in pre-market trading. Outset Medical will release financial results for the first quarter after the close of trading on Wednesday, May 7.</li>
<li>National Energy Services Reunited Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NESR#NASDAQ">NESR</a>) shares fell 16.4% to $5.00 in pre-market trading.</li>
<li>INmune Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) fell 16.1% to $6.11 in pre-market trading.</li>
<li>Gulf Resources, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GURE#NASDAQ">GURE</a>) shares dipped 11.7% to $0.6890 in pre-market trading after dipping over 17% on Monday.</li>
<li>USA Rare Earth, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USAR#NASDAQ">USAR</a>) declined 9.3% to $10.65 in pre-market trading. USA Rare Earth will release financial results for the first quarter, after the closing bell on Wednesday, May 14.</li>
<li>Tyra Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TYRA#NASDAQ">TYRA</a>) fell 7.3% to $8.40 in today's pre-market trading.</li>
<li>SITE Centers Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SITC#NYSE">SITC</a>) dipped 5.7% to $11.01 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44896269/how-to-earn-500-a-month-from-3m-stock-ahead-of-q1-earnings">How To Earn $500 A Month From 3M Stock Ahead Of Q1 Earnings</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Markets

ADPT

CALX

GELS

GURE

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

MKDW

MULN

NESR

SHF Holdings, Inc. - Class A Common Stock

SHFS

SITC

SLSR

SUNE

TNMG

TYRA

USAR

Why Calix Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket

INmune Bio Announced A Major Intellectual Property Milestone With Respect To Its Next-generation Mesenchymal Stromal Cell (MSC) Product, CORDStrom

Stevenage, UK, and Boca Raton, Florida, US, April 14, 2025 (GLOBE NEWSWIRE) --&nbsp; INmune Bio Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) a clinical-stage biotechnology company targeting inflammation and immunology through the innate immune system has partnered with the Cell and Gene Therapy Catapult (CGT Catapult) to establish large-scale, commercial-ready manufacturing for its cell therapy platforms. CGT Catapult is an independent technology and innovation organization specializing in the advancement of the cell and gene therapy industry. It was established by and works in partnership with Innovate UK.
INmune Bio's therapies harness the innate immune system, the body's first line of defense, to treat diseases including Alzheimer's, prostate cancer, and recessive dystrophic epidermolysis bullosa (RDEB), a rare genetic skin disorder. With active trials across the UK, Europe, Australia, Canada and the US, the company is advancing a diversified portfolio addressing significant unmet medical needs.
The collaboration builds on INmune Bio's existing manufacturing base at the Royal Free Hospital and leverages CGT Catapult's expertise at its Stevenage Manufacturing Innovation Centre. The initial focus is on scaling production of CORDStromTM, a promising therapy for RDEB. In a recent Phase 2 randomized trial, CORDStromTM reduced pain and itch while showing potential to improve skin integrity and disease activity. INmune Bio estimates that approximately 4,000 children with intermediate to severe RDEB in the US, UK and EU could benefit, positioning CORDStromTM for clinical trial supply and eventual Biologics License Application (BLA) and Marketing Authorization Application (MAA) submissions.&nbsp; The Company believes that CORDStrom&#x2122; could be the first cell therapy to address the systemic nature of RDEB.
Following CORDStromTM, INmune Bio plans to transition production of INKmune&#xAE;, its NK-priming cell medicine for solid tumors, to the same facility, supporting ongoing and future trials in the US and UK, including the Phase 2 study in metastatic castration-resistant prostate cancer.
This partnership with CGT Catapult accelerates the Company's path to commercialization by delivering efficient, scalable manufacturing while preserving operational control.

INmune Bio Partners With Cell And Gene Therapy Catapult To Establish Large-Scale, Commercial-Ready Manufacturing For Cell Therapy Platforms

INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.53) by 24.53 percent. This is a 14.89 percent increase over losses of $(0.47) per share from the same period last year.

INmune Bio Q4 EPS $(0.40) Beats $(0.53) Estimate

<h3>Companies Reporting Before The Bell</h3>
• Tsakos Energy Navigation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEN#NYSE">TEN</a>) is projected to report quarterly earnings at $0.40 per share on revenue of $154.43 million. 
• Worksport (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKSP#NASDAQ">WKSP</a>) is projected to report quarterly loss at $1.40 per share on revenue of $2.90 million. 
• PDS Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDSB#NASDAQ">PDSB</a>) is projected to report earnings for its fourth quarter. 
• FitLife Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTLF#NASDAQ">FTLF</a>) is estimated to report quarterly earnings at $0.20 per share on revenue of $14.95 million. 
• ADC Therapeutics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADCT#NYSE">ADCT</a>) is expected to report quarterly loss at $0.35 per share on revenue of $19.67 million. 
• Telesat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSAT#NASDAQ">TSAT</a>) is expected to report earnings for its fourth quarter. 
• Acumen Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABOS#NASDAQ">ABOS</a>) is expected to report earnings for its fourth quarter. 
• Bitfarms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BITF#NASDAQ">BITF</a>) is estimated to report quarterly loss at $0.04 per share on revenue of $53.82 million. 
• Winnebago Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WGO#NYSE">WGO</a>) is expected to report quarterly earnings at $0.19 per share on revenue of $608.95 million. 
• BK Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BKTI#AMEX">BKTI</a>) is estimated to report quarterly earnings at $0.35 per share on revenue of $16.80 million. 
• Edap TMS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDAP#NASDAQ">EDAP</a>) is estimated to report quarterly loss at $0.11 per share on revenue of $20.83 million. 
• TriSalus Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLSI#NASDAQ">TLSI</a>) is likely to report quarterly loss at $0.35 per share on revenue of $8.24 million. 
• BIO-key Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKYI#NASDAQ">BKYI</a>) is likely to report quarterly loss at $0.35 per share on revenue of $2.29 million. 
• Icecure Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCM#NASDAQ">ICCM</a>) is expected to report quarterly loss at $0.07 per share on revenue of $1.07 million. 
• Jiayin Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFIN#NASDAQ">JFIN</a>) is likely to report earnings for its fourth quarter. 
• Ascentage Pharma Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPG#NASDAQ">AAPG</a>) is projected to report earnings for its fourth quarter. 
• Urban One (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UONEK#NASDAQ">UONEK</a>) is estimated to report earnings for its fourth quarter. 
• Urban One (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UONE#NASDAQ">UONE</a>) is projected to report earnings for its fourth quarter. 
• TD Synnex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNX#NYSE">SNX</a>) is likely to report quarterly earnings at $2.91 per share on revenue of $14.79 billion. 
• Sachem Cap (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SACH#AMEX">SACH</a>) is projected to report quarterly loss at $0.46 per share on revenue of $14.49 million. 
• Ermenegildo Zegna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZGN#NYSE">ZGN</a>) is likely to report earnings for its Fiscal Year 2024. 
• Innate Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPHA#NASDAQ">IPHA</a>) is projected to report earnings for its Fiscal Year 2024. 
<h3>Companies Reporting After The Bell</h3>
• Dolphin Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLPN#NASDAQ">DLPN</a>) is likely to report quarterly earnings at $0.04 per share on revenue of $13.52 million. 
• Relmada Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLMD#NASDAQ">RLMD</a>) is projected to report earnings for its fourth quarter. 
• Draganfly (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPRO#NASDAQ">DPRO</a>) is projected to report quarterly loss at $0.66 per share on revenue of $1.45 million. 
• Gevo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) is projected to report quarterly loss at $0.09 per share on revenue of $3.85 million. 
• SeaStar Medical Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICU#NASDAQ">ICU</a>) is likely to report earnings for its fourth quarter. 
• INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) is projected to report earnings for its fourth quarter. 
• TMC Metals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMC#NASDAQ">TMC</a>) is estimated to report earnings for its fourth quarter. 
• Strata Skin Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSKN#NASDAQ">SSKN</a>) is expected to report quarterly loss at $0.40 per share on revenue of $9.03 million. 
• IZEA Worldwide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IZEA#NASDAQ">IZEA</a>) is expected to report quarterly loss at $0.08 per share on revenue of $13.00 million. 
• Yxt.Com Group Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YXT#NASDAQ">YXT</a>) is expected to report earnings for its fourth quarter. 
• TSS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSSI#NASDAQ">TSSI</a>) is expected to report earnings for its fourth quarter. 
• BioRestorative Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>) is likely to report quarterly loss at $0.27 per share on revenue of $475 thousand. 
• Direct Digital Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRCT#NASDAQ">DRCT</a>) is likely to report quarterly loss at $0.67 per share on revenue of $12.31 million. 
• Faraday Future (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFAI#NASDAQ">FFAI</a>) is expected to report earnings for its fourth quarter. 
• 374Water (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCWO#NASDAQ">SCWO</a>) is likely to report quarterly loss at $0.02 per share on revenue of $100 thousand. 
• Lantern Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>) is estimated to report earnings for its fourth quarter. 
• Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) is projected to report quarterly loss at $0.95 per share on revenue of $920 thousand. 
• Unusual Machines (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UMAC#AMEX">UMAC</a>) is likely to report earnings for its fourth quarter. 
• BioAtla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAB#NASDAQ">BCAB</a>) is expected to report earnings for its fourth quarter. 
• Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) is projected to report quarterly loss at $0.51 per share on revenue of $1.19 million. 
• VirTra (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTSI#NASDAQ">VTSI</a>) is projected to report quarterly earnings at $0.07 per share on revenue of $8.09 million. 
• Forian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORA#NASDAQ">FORA</a>) is estimated to report quarterly earnings at $0.02 per share on revenue of $5.37 million. 
• Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) is likely to report quarterly loss at $0.31 per share on revenue of $6.20 million. 
• Beachbody Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BODI#NYSE">BODI</a>) is likely to report quarterly loss at $1.52 per share on revenue of $81.71 million. 
• Stardust Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDST#NASDAQ">SDST</a>) is expected to report earnings for its fourth quarter. 
• Valhi (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VHI#NYSE">VHI</a>) is expected to report quarterly earnings at $0.03 per share on revenue of $19.48 million. 
• Nutex Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>) is projected to report quarterly earnings at $0.00 per share on revenue of $81.13 million. 
• Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) is projected to report quarterly loss at $0.05 per share on revenue of $12.80 million. 
• AAR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIR#NYSE">AIR</a>) is projected to report quarterly earnings at $0.96 per share on revenue of $679.95 million. 
• Oxford Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXM#NYSE">OXM</a>) is expected to report quarterly earnings at $1.28 per share on revenue of $383.94 million. 
• P3 Health Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIII#NASDAQ">PIII</a>) is expected to report quarterly loss at $0.17 per share on revenue of $385.80 million. 
• Co-Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CODX#NASDAQ">CODX</a>) is likely to report quarterly loss at $0.34 per share on revenue of $375 thousand. 
• Argan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGX#NYSE">AGX</a>) is estimated to report quarterly earnings at $1.11 per share on revenue of $212.05 million. 
• HireQuest (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQI#NASDAQ">HQI</a>) is likely to report quarterly earnings at $0.19 per share on revenue of $9.30 million. 
• Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) is expected to report quarterly earnings at $5.65 per share on revenue of $3.52 billion. 
• Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) is likely to report quarterly loss at $0.11 per share on revenue of $294 thousand. 
• KULR Tech Gr (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KULR#AMEX">KULR</a>) is estimated to report quarterly loss at $0.02 per share on revenue of $2.87 million. 
• Blaize Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZAI#NASDAQ">BZAI</a>) is expected to report earnings for its fourth quarter. 
• Sky Harbour Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKYH#NYSE">SKYH</a>) is expected to report quarterly loss at $0.06 per share on revenue of $4.15 million. 
• Better Choice Co (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BTTR#AMEX">BTTR</a>) is likely to report earnings for its fourth quarter. 
• Pulse Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLSE#NASDAQ">PLSE</a>) is likely to report earnings for its fourth quarter. 
• Braze (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRZE#NASDAQ">BRZE</a>) is expected to report quarterly earnings at $0.04 per share on revenue of $155.25 million. 
• Lulus Fashion Lounge (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVLU#NASDAQ">LVLU</a>) is likely to report quarterly loss at $0.14 per share on revenue of $68.43 million. 
• Spectral AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDAI#NASDAQ">MDAI</a>) is expected to report quarterly loss at $0.14 per share on revenue of $6.83 million. 
• Barfresh Food Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRFH#NASDAQ">BRFH</a>) is expected to report quarterly loss at $0.01 per share on revenue of $4.17 million. 
• Abacus Global Management (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABL#NASDAQ">ABL</a>) is expected to report quarterly earnings at $0.14 per share on revenue of $30.18 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

INmune Bio

Unusual Options Activity for

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL